ArticlePharmacoEconomics2018
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Josh J Carlson et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this paperpooled itcites it